An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease
ConclusionsAclidinium/formoterol 400/12 µg twice daily was well-tolerated in patients from China with moderate-to-severe COPD. Safety findings were consistent with the known safety profile.Clinical Trial IdentifierClinicalTrials.gov, NCT03276078. (Source: Drugs in R&D)
Source: Drugs in R&D - February 8, 2022 Category: Drugs & Pharmacology Source Type: research
Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial
ConclusionIn patients with moderate-to-severe COPD and CV risk factors, the addition of aclidinium to maintenance therapy with LABA or LABA + ICS provided further benefit.Trial RegistrationClinicalTrials.gov identifier NCT01966107. (Source: Advances in Therapy)
Source: Advances in Therapy - September 15, 2021 Category: Drugs & Pharmacology Source Type: research
Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update
Expert Rev Respir Med. 2021 Jun 17:1-14. doi: 10.1080/17476348.2021.1920403. Online ahead of print.ABSTRACTIntroduction: Aclidinium/formoterol is a long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) dual bronchodilator used as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). The efficacy of aclidinium/formoterol has been demonstrated consistently in patients with moderate-to-severe COPD versus placebo and monocomponents, with a comparable safety profile.Areas covered: This review examines recent research findings that expand our understanding of the impact of ...
Source: Expert Review of Respiratory Medicine - June 17, 2021 Category: Respiratory Medicine Authors: Anthony D D'Urzo Dave Singh James F Donohue Kenneth R Chapman Robert A Wise Source Type: research
Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update
Expert Rev Respir Med. 2021 Jun 17:1-14. doi: 10.1080/17476348.2021.1920403. Online ahead of print.ABSTRACTIntroduction: Aclidinium/formoterol is a long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) dual bronchodilator used as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). The efficacy of aclidinium/formoterol has been demonstrated consistently in patients with moderate-to-severe COPD versus placebo and monocomponents, with a comparable safety profile.Areas covered: This review examines recent research findings that expand our understanding of the impact of ...
Source: Respiratory Care - June 17, 2021 Category: Respiratory Medicine Authors: Anthony D D'Urzo Dave Singh James F Donohue Kenneth R Chapman Robert A Wise Source Type: research
Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update
Expert Rev Respir Med. 2021 Jun 17:1-14. doi: 10.1080/17476348.2021.1920403. Online ahead of print.ABSTRACTIntroduction: Aclidinium/formoterol is a long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) dual bronchodilator used as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). The efficacy of aclidinium/formoterol has been demonstrated consistently in patients with moderate-to-severe COPD versus placebo and monocomponents, with a comparable safety profile.Areas covered: This review examines recent research findings that expand our understanding of the impact of ...
Source: Expert Review of Respiratory Medicine - June 17, 2021 Category: Respiratory Medicine Authors: Anthony D D'Urzo Dave Singh James F Donohue Kenneth R Chapman Robert A Wise Source Type: research
A comparison of the efficacy and safety of combined aclidinium bromide and formoterol fumarate in the treatment of chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis
Conclusion:
The conclusion of the present study will provide evidence to judge whether combined aclidinium bromide and formoterol fumarate is an effective and safety intervention in the treatment of COPD.
Systematic review registration number:
INPLASY202070063. (Source: Medicine)
Source: Medicine - November 20, 2020 Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research
